Rhumbline Advisers Has $163.07 Million Holdings in Zoetis Inc. $ZTS

Rhumbline Advisers increased its position in shares of Zoetis Inc. (NYSE:ZTS) by 2.0% during the third quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm owned 1,114,477 shares of the company’s stock after purchasing an additional 22,136 shares during the period. Rhumbline Advisers owned about 0.25% of Zoetis worth $163,070,000 at the end of the most recent reporting period.

Other hedge funds and other institutional investors have also recently bought and sold shares of the company. Impax Asset Management Group plc increased its holdings in Zoetis by 43.9% in the 3rd quarter. Impax Asset Management Group plc now owns 1,693,701 shares of the company’s stock valued at $247,822,000 after buying an additional 516,705 shares during the period. Krilogy Financial LLC boosted its position in shares of Zoetis by 55.2% during the 3rd quarter. Krilogy Financial LLC now owns 27,536 shares of the company’s stock valued at $4,029,000 after acquiring an additional 9,798 shares in the last quarter. Stratos Wealth Partners LTD. increased its stake in Zoetis by 5.6% in the third quarter. Stratos Wealth Partners LTD. now owns 68,818 shares of the company’s stock valued at $10,070,000 after acquiring an additional 3,661 shares during the period. Baader Bank Aktiengesellschaft raised its position in Zoetis by 647.5% in the third quarter. Baader Bank Aktiengesellschaft now owns 26,834 shares of the company’s stock worth $3,903,000 after purchasing an additional 23,244 shares in the last quarter. Finally, Waterway Wealth Management LLC lifted its stake in Zoetis by 11.6% during the third quarter. Waterway Wealth Management LLC now owns 4,951 shares of the company’s stock worth $724,000 after purchasing an additional 516 shares during the period. 92.80% of the stock is owned by institutional investors.

Zoetis Trading Up 0.6%

NYSE:ZTS opened at $128.85 on Thursday. The company has a current ratio of 3.64, a quick ratio of 2.28 and a debt-to-equity ratio of 1.31. Zoetis Inc. has a 1-year low of $115.25 and a 1-year high of $177.00. The firm has a market capitalization of $56.79 billion, a price-to-earnings ratio of 21.69, a PEG ratio of 2.21 and a beta of 0.96. The business’s 50-day moving average price is $124.16 and its two-hundred day moving average price is $135.79.

Zoetis (NYSE:ZTS) last posted its earnings results on Thursday, February 12th. The company reported $1.48 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.40 by $0.08. Zoetis had a return on equity of 57.19% and a net margin of 28.21%. On average, equities analysts expect that Zoetis Inc. will post 6.07 earnings per share for the current year.

Zoetis Announces Dividend

The company also recently declared a quarterly dividend, which will be paid on Tuesday, June 2nd. Stockholders of record on Monday, April 20th will be given a dividend of $0.53 per share. This represents a $2.12 dividend on an annualized basis and a dividend yield of 1.6%. The ex-dividend date of this dividend is Monday, April 20th. Zoetis’s dividend payout ratio (DPR) is currently 35.69%.

Wall Street Analysts Forecast Growth

Several brokerages recently commented on ZTS. HSBC set a $140.00 price target on Zoetis in a research note on Wednesday, December 10th. Barclays initiated coverage on shares of Zoetis in a report on Monday, December 8th. They issued an “equal weight” rating and a $136.00 price target for the company. Wall Street Zen upgraded Zoetis from a “hold” rating to a “buy” rating in a research report on Friday, January 23rd. Stifel Nicolaus decreased their price target on Zoetis from $140.00 to $130.00 and set a “hold” rating on the stock in a report on Tuesday, November 18th. Finally, KeyCorp started coverage on Zoetis in a report on Thursday, November 20th. They set a “sector weight” rating for the company. Five analysts have rated the stock with a Buy rating, seven have given a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat, the company has a consensus rating of “Hold” and a consensus price target of $152.45.

Zoetis Company Profile

Zoetis Inc (NYSE: ZTS) is a global animal health company that develops, manufactures and markets a broad portfolio of products and services for companion animals and livestock. The company’s offerings include pharmaceuticals, vaccines and biologics, parasiticides and anti-infectives, as well as diagnostic instruments, consumables and laboratory testing services. Zoetis serves the veterinary community, livestock producers and other animal-health customers with products designed to prevent, detect and treat disease and to support animal productivity and welfare.

Zoetis traces its roots to the animal health business of Pfizer and became an independent, publicly traded company following a 2013 separation and initial public offering.